2020
Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors
Kim J, Zimmerman M, Hong J. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. Journal Of Gastrointestinal Oncology 2020, 11: 601-608. PMID: 32655939, PMCID: PMC7340808, DOI: 10.21037/jgo.2019.11.03.Peer-Reviewed Original ResearchPost-OLT outcomesOrthotopic liver transplantationNeuroendocrine tumorsLiver metastasesLiver transplantationTreatment of unresectable hepatic metastasesPatients of neuroendocrine tumorsRecurrence-free patient survivalUnresectable hepatic metastasesPrediction of survival outcomesPrimary neuroendocrine tumorsUnresectable liver metastasesReview patient selection criteriaLiver neuroendocrine tumorsRate of recurrencePatient selection criteriaHepatic metastasesPrognostic factorsRare neoplasmsPost-OLTDefinitive treatmentMetastatic spreadSurvival outcomesPatient survivalMultiple tumors
2006
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer
Murthy R, Oh Y, Tam A, Gupta S, Madoff D, Glisson B. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Journal Of Clinical Oncology 2006, 24: 17122-17122. DOI: 10.1200/jco.2006.24.18_suppl.17122.Peer-Reviewed Original ResearchHepatic metastasesSIR-SpheresLung cancerLiver metastasesSystemic therapyAdvanced liver metastasesLiver-dominant metastasesPrimary lung malignancyRegional hepatic therapyUnresectable hepatic metastasesColorectal liver metastasesLocal disease controlMetastatic lung cancerYttrium-90 Microsphere TreatmentMajority of patientsProgression of diseaseGr. 1Dominant metastasesStable diseaseVisceral arteriographyMedian doseSystemic chemotherapyArterial embolizationLine therapyMedian interval
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply